US-Listed In Vitro & In Vivo Diagnostic Substances — Operating Income Percentiles, FY 2023

Population: 17 US-listed companies (SIC 2835), fiscal year 2023; fiscal year ends 2023-12-31 to 2024-05-31.

Fiscal year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · latest

10th percentile	$-195.7M
25th percentile	$-35.6M
Median	$-7.2M
75th percentile	$2.0M
90th percentile	$229.3M
Mean	$34.2M
Minimum	$-515.3M
Maximum	$1.1B

Methodology & sources
Operating Income as filed, one fiscal year per company; percentiles computed in the database via percentile_cont, never by a model. Fiscal year 2023 = fiscal years ending 2023-06-01 to 2024-05-31 (majority-overlap rule; June-ending fiscal years count toward the ending calendar year).
Source: SEC EDGAR filings (public domain). Data: FACTANKER registry, precomputed 2026-09-03.

Evidence samples

Latest Operating Income percentiles (live) · All In Vitro & In Vivo Diagnostic Substances benchmarks · All industries

Cite as: FACTANKER, https://factanker.com/industries/sic-2835/operating-income/2023